- The FDA grants Priority Review designation for the evaluation of medicines that, if approved, would provide a significant ...

SKYTROFA® (lonapegsomatropin) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of paediatric ...

Voxzogo drives BioMarin’s growth but faces looming competition from Ascendis’ TransCon CNP. BioMarin’s acquisition of Inozyme adds pipeline depth but won’t offset expected declines in key ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

American Airlines is looking to take some of the anxiety away from some of those flights by introducing new technology for customers with connections. "If the airline determines it can delay the ...

A futuristic fix for depression is here — and it doesn’t involve prescription drugs or a shrink. The first-of-its-kind solution from GrayMatters Health uses something called “self ...

Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $183.00. Ascendis Pharma A/S ( NASDAQ:ASND – Get Free Report ) last announced its earnings results on Thursday, May 1st.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...